You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

393 Results
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Jun 2025
Document
Nov 2022
Document
Nov 2022
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Panitumumab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
encorafenib,
PANitumumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Guidelines and Advice
Status: Current
ID: PET 2022-1
Jan 2023
Document
Jan 2023
Document
Jan 2023
Document
Jan 2023
Document
Jan 2023
Drug
Other Name(s): Padcev®
Quick Link(s): Drug Monograph, Patient Info Sheet
Aug 2025
Drug
Other Name(s): Braftovi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Apr 2024
.

Pages